Lords Mark Industries acquires Radiotone for ₹4.50 crore to expand energy division

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Lords Mark Industries acquired Radio Electric Private Limited for ₹4.50 crore in cash
  • The deal secures 100% equity stake in the maker of the Radiotone brand
  • Target entity is debt-free with exports to seven international markets
  • Acquisition supports expansion into Battery Energy Storage Systems and medical devices
powered bylight_fuzz_icon
53359968

*this image is generated using AI for illustrative purposes only.

Lords Mark Industries Limited has completed the acquisition of Radio Electric Private Limited, the maker of the 'Radiotone' brand, for ₹4.50 crore. The deal marks a strategic expansion into specialised electrical manufacturing and engineering under the company's Lighting & Energy Division.

The acquisition was intimated to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction involved the purchase of a controlling stake, specifically 100% equity, through cash consideration. The target entity is registered in Maharashtra and operates within the electrical manufacturing sector.

Target entity profile

Radio Electric Private Limited was founded in 1939 and holds an 87-year engineering heritage. It is recognised as a pioneer of double-layer Variacs introduced between 1979 and 1980. The company specialises in variable autotransformers, toroidal transformers, voltage isolation transformers, and high-current manufacturing.

The filing describes the target as a profitable, debt-free operating business with established domestic clientele across 40-50 blue-chip accounts. It also maintains repeat exports across seven international markets.

Acquisition details

Parameter Details
Target Entity Radio Electric Private Limited
Consideration ₹4.50 crore
Type of Acquisition Completed acquisition of shares/control
Stake Acquired 100% equity
Related Party Transaction No
Promoter Interest None

Strategic rationale

The company outlined several synergies expected from the acquisition:

  • Product Integration: Brings nearly nine decades of engineering expertise and specialised transformer technology into Lords Mark Industries.
  • BESS & Medical Devices: Provides a strategic edge in the Battery Energy Storage Systems segment and enables in-house component manufacturing to improve profitability in the medical device business.
  • Capacity Utilization: Offers immediate headroom to scale production without heavy upfront capital expenditure, as the operating manufacturing infrastructure is currently at ~50% single-shift capacity.
  • Global Export Footprint: Secures repeat export channels across seven international markets, including Europe, the USA, Canada, South Africa, Dubai, and the Philippines.

What the numbers show

The acquisition price of ₹4.50 crore for a debt-free entity with an 87-year heritage suggests a valuation focused on asset acquisition and market access rather than high-growth multiples. The disclosure that the target’s infrastructure is at ~50% single-shift capacity indicates potential for operational leverage, allowing the acquirer to increase output without proportional increases in fixed costs or capital expenditure.

Historical Stock Returns for Lords Mark Industries

1 Day5 Days1 Month6 Months1 Year5 Years
-1.01%-0.08%-4.51%0.0%0.0%0.0%

How will Lords Mark Industries integrate Radio Electric's transformer technology into its existing Battery Energy Storage Systems (BESS) product roadmap?

What specific capital expenditure plans are in place to scale Radio Electric's production capacity from the current 50% single-shift utilization to meet increased demand?

How does the acquisition of 'Radiotone' brand equity and export channels align with Lords Mark's long-term revenue diversification targets beyond the domestic Indian market?

like20
dislike

Lords Mark Industries secures MHRA registration for UK IVD portfolio

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • MHRA registration for IVD portfolio dated September 24, 2026
  • Commercial sales in UK to begin December 2026, two months early
  • Registration covers haematological and clinical chemistry analysers
  • Pathology laboratory operations planned for January 2027
powered bylight_fuzz_icon
52716002

*this image is generated using AI for illustrative purposes only.

Lord's Mark Industries Limited has secured Medicines and Healthcare products Regulatory Agency (MHRA) registration for its In-Vitro Diagnostic (IVD) portfolio, enabling commercial sales in the United Kingdom from December 2026.

The registration, dated September 24, 2026, lists the company as a registered manufacturer. It covers specific IVD categories including haematological cell analysers, multiple clinical chemistry analysers, buffered sample diluents, and instrument cleaning agents. This milestone follows the recent MHRA registration for the company's AI-powered Renalyx haemodialysis system announced in September.

Accelerated commercial timeline

The company plans to commence commercial sales of its IVD products in the UK market from December 2026. This start date is approximately two months ahead of the earlier schedule. The accelerated timeline allows Lords Mark to leverage the UK as an international platform while pursuing opportunities across UK-allied markets, subject to local regulatory requirements.

Integrated healthcare strategy

Beyond product exports, the company is expanding into healthcare delivery services. A pathology laboratory is scheduled to commence operations in January 2027. This initiative aims to integrate diagnostic products with laboratory capabilities and healthcare delivery.

Dr. Sachidanand Upadhyay, MD & CEO, stated that the registrations demonstrate ambition beyond a single healthcare product. He noted the goal of building a broader diagnostics and healthcare platform with commercialisation planned ahead of schedule.

What the numbers show

The sequence of regulatory approvals highlights a rapid diversification of the company's international footprint within a single month. The MHRA registration for the Renalyx system occurred in September, followed immediately by the IVD portfolio registration on September 24, 2026. This tight clustering of approvals supports the decision to pull forward commercial sales by two months, indicating readiness for immediate market entry across both renal care technology and diagnostics segments.

Historical Stock Returns for Lords Mark Industries

1 Day5 Days1 Month6 Months1 Year5 Years
-1.01%-0.08%-4.51%0.0%0.0%0.0%

How will the accelerated December 2026 UK launch impact Lords Mark's revenue guidance for the upcoming fiscal year?

What specific regulatory hurdles remain for expanding the IVD portfolio into other UK-allied markets like the EU or Canada?

How does the integration of the January 2027 pathology lab alter the company's cost structure and gross margin profile compared to pure product exports?

like19
dislike

More News on Lords Mark Industries

1 Year Returns:0.00%